Novartis AG ADR (NVS)vsPuma Biotechnology Inc (PBYI)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
PBYI
Puma Biotechnology Inc
$7.48
-0.80%
HEALTHCARE · Cap: $382.08M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 24675% more annual revenue ($56.58B vs $228.37M). NVS leads profitability with a 23.9% profit margin vs 13.6%. PBYI appears more attractively valued with a PEG of 0.03. PBYI earns a higher WallStSmart Score of 71/100 (B).
NVS
Buy51
out of 100
Grade: C-
PBYI
Strong Buy71
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
+76.6%
Fair Value
$28.43
Current Price
$7.48
$20.95 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Growing faster than its price suggests
Every $100 of equity generates 28 in profit
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 22.7%
Revenue surging 27.7% year-over-year
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Smaller company, higher risk/reward
Earnings declined 34.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : PBYI
The strongest argument for PBYI centers on PEG Ratio, Return on Equity, P/E Ratio. Revenue growth of 27.7% demonstrates continued momentum. PEG of 0.03 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : PBYI
The primary concerns for PBYI are Market Cap, EPS Growth.
Key Dynamics to Monitor
NVS profiles as a declining stock while PBYI is a growth play — different risk/reward profiles.
PBYI carries more volatility with a beta of 1.18 — expect wider price swings.
PBYI is growing revenue faster at 27.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
PBYI scores higher overall (71/100 vs 51/100) and 27.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Puma Biotechnology Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States and internationally. The company is headquartered in Los Angeles, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?